Zacks Research Lifts Earnings Estimates for Aethlon Medical

Aethlon Medical, Inc. (NASDAQ:AEMD) – Research analysts at Zacks Research upped their Q2 2027 earnings per share (EPS) estimates for Aethlon Medical in a research report issued on Wednesday, August 19th. Zacks Research analyst M. Marin now forecasts that the medical equipment provider will post earnings per share of ($2.17) for the quarter, up from their previous forecast of ($4.05). The consensus estimate for Aethlon Medical’s current full-year earnings is ($8.53) per share. Zacks Research also issued estimates for Aethlon Medical’s Q3 2027 earnings at ($2.17) EPS, Q4 2027 earnings at ($2.18) EPS and FY2027 earnings at ($10.55) EPS.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing the consensus estimate of ($3.92) by ($0.10).

Several other analysts have also recently weighed in on AEMD. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 target price on shares of Aethlon Medical in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $1.50.

Aethlon Medical Stock Down 2.9%

Shares of Aethlon Medical stock opened at $2.70 on Friday. The business has a 50 day moving average of $4.26 and a 200 day moving average of $8.44. Aethlon Medical has a 52 week low of $2.63 and a 52 week high of $137.00. The company has a market cap of $1.92 million, a PE ratio of -0.08 and a beta of 1.41.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 1.99% of the company’s stock.

Trending Headlines about Aethlon Medical

Here are the key news stories impacting Aethlon Medical this week:

• Positive Sentiment: Zacks Research raised its FY2027 EPS forecast to a loss of $10.55 per share from a projected loss of $16.15, while increasing its Q2, Q3 and Q4 2027 estimates to losses of approximately $2.17–$2.18 per share from $4.05. The revisions suggest analysts expect lower expenses or improved operating performance, though Aethlon remains unprofitable. Zacks Research estimate revisions
• Neutral Sentiment: Aethlon’s oncology study is advancing, while the company continues cost-efficient preclinical work involving other diseases. The update may support the company’s longer-term therapeutic pipeline, but it does not provide a near-term revenue or approval catalyst. AEMD: Oncology Study Advances; Cost-Efficient Preclinical Activities Regarding Other Diseases Continue
• Negative Sentiment: HC Wainwright maintained a Neutral rating and a $1.50 price target, below AEMD’s recent trading level. Its forecasts call for continued losses in FY2027 through FY2030, with EPS estimates of ($0.92), ($0.57), ($0.69) and ($0.22), respectively. This valuation gap and ongoing losses can weigh on investor sentiment. HC Wainwright Predicts Aethlon Medical FY2031 Earnings
• Negative Sentiment: Aethlon’s financial outlook remains highly speculative. The company previously reported a quarterly loss of $4.02 per share, missing the $3.92 consensus estimate, and analysts still expect a full-year loss of approximately $8.53 per share. With the shares far below their 50-day and 200-day moving averages, technical and fundamental factors remain unfavorable.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.